Search Results - "Hoentjen, F."

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? by Derikx, L. A. A. P., Hoentjen, F.

“…LINKED CONTENT This article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and…”
Get full text

Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients by de Jong, M E, Smits, L J T, van Ruijven, B, den Broeder, N, Russel, M G V M, Römkens, T E H, West, R L, Jansen, J M, Hoentjen, F

“…Abstract Background and Aims There is paucity of data on safety and efficacy of anti-tumour necrosis factor [TNF] in elderly inflammatory bowel disease [IBD]…”
Get full text

Comment on: Surveillance pouchoscopy for dysplasia: Cleveland Clinic Ileoanal Pouch Anastomosis Database by Derks, M E W, Te Groen, M, Hoentjen, F, Derikx, L A A P

Get full text

Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease by Kreijne, J. E., Goetgebuer, R. L., Erler, N. S., De Boer, N. K., Siebers, A. G., Dijkstra, G., Kemenade, F. A., Hoentjen, F., Oldenburg, B., Meulen, A. E., Ponsioen, C. I. J., Pierik, M. J., Woude, C. J., Vries, A. C.

“…Summary Background Women with inflammatory bowel disease (IBD) are at increased risk of high‐grade cervical intraepithelial neoplasia and cervical cancer…”
Get full text

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study by Smits, L J T, Pauwels, R W M, Kievit, W, de Jong, D J, de Vries, A C, Hoentjen, F, van der Woude, C J

“…IntroductionAdalimumab is effective for maintenance of remission in patients with Crohn’s disease (CD) at a dose of 40 mg subcutaneously every 2 weeks…”
Get full text

Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study by Goetgebuer, R L, Kreijne, J E, Aitken, C A, Dijkstra, G, Hoentjen, F, de Boer, N K, Oldenburg, B, van der Meulen, A E, Ponsioen, C I J, Pierik, M J, van Kemenade, F J, de Kok, I M C M, Siebers, A G, Manniën, J, van der Woude, C J, de Vries, A C

“…Women with inflammatory bowel disease [IBD] may be at higher risk for cervical intraepithelial neoplasia [CIN]. However, data are conflicting. The aim of this…”
Get full text

Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn’s Disease by Savelkoul, E H J, Maas, M H J, Bourgonje, A R, Crouwel, F, Biemans, V B C, den Broeder, N, Russel, M G V M, Römkens, T E H, de Boer, N K, Dijkstra, G, Hoentjen, F

“…Abstract Background and Aims Both methotrexate and tioguanine can be considered as treatment options in patients with Crohn’s disease after failure of…”
Get full text

Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes by Voskuil, M D, Spekhorst, L M, van der Sloot, K W J, Jansen, B H, Dijkstra, G, van der Woude, C J, Hoentjen, F, Pierik, M J, van der Meulen, A E, de Boer, N K H, Löwenberg, M, Oldenburg, B, Festen, E A M, Weersma, R K

“…Abstract Background and Aims Inflammatory bowel disease [IBD] phenotypes are very heterogeneous between patients, and current clinical and molecular…”
Get full text

Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment by Dieleman, L A, Goerres, M S, Arends, A, Sprengers, D, Torrice, C, Hoentjen, F, Grenther, W B, Sartor, R B

“…Background and aims:Bacteroides vulgatus induces colitis in gnotobiotic HLA-B27 transgenic (TG) rats while broad spectrum antibiotics prevent and treat colitis…”
Get full text

The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study by Spekhorst, L M, Severs, M, de Boer, N K H, Festen, E A M, Fidder, H H, Hoentjen, F, Imhann, F, de Jong, D J, van der Meulen-de Jong, A E, Pierik, M J, van der Woude, C J, Dijkstra, G, Ponsioen, C Y, Löwenberg, M, Oldenburg, B, Weersma, R K

“…The number of patients with inflammatory bowel disease [IBD], of non-Caucasian descent in Western Europe, is increasing. We aimed to explore the impact of…”
Get full text

Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice by Hoentjen, F, Harmsen, H J M, Braat, H, Torrice, C D, Mann, B A, Sartor, R B, Dieleman, L A

“…Background and aims: Multiple rodent models implicate resident intestinal bacteria in the pathogenesis of chronic immune mediated intestinal inflammation…”
Get full text

Effect of Circulating Peptide YY on Gallbladder Emptying in Humans by HOENTJEN, F, HOPMAN, W. P. M, JANSEN, J. B. M. J

“…Background: To further establish its role in the ileal brake mechanism, we determined the effect of the distal gut hormone peptide YY (PYY) on gallbladder…”
Get full text

Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA‐B27 transgenic rats by DIELEMAN, L. A., HOENTJEN, F., QIAN, B.‐F., SPRENGERS, D., TJWA, E., TORRES, M. F., TORRICE, C. D., SARTOR, R. B., TONKONOGY, S. L.

“…SUMMARY Germ‐free HLA‐B27 transgenic (TG) rats do not develop colitis, but colonization with specific pathogen‐free (SPF) bacteria induces colitis accompanied…”
Get full text

Intestinal ischaemia caused by mesenteric inflammatory veno-occlusive disease by ERYIGIT, E, HOENTJEN, F, BARBE, E, VAN MEYEL, J. J. M

“…Mesenteric inflammatory veno-occlusive disease (MIVOD) is a rare cause of intestinal ischaemia. Previously described cases of MIVOD demonstrate vasculitis in…”
Get full text

Adoptive transfer of nontransgenic mesenteric lymph node cells induces colitis in athymic HLA‐B27 transgenic nude rats by Hoentjen, F., Tonkonogy, S. L., Liu, B., Sartor, R. B., Taurog, J. D., Dieleman, L. A.

“…Summary HLA‐B27 transgenic (TG) rats develop spontaneous colitis when colonized with intestinal bacteria, whereas athymic nude (rnu/rnu) HLA‐B27 TG rats remain…”
Get full text

P199 Clonal patterns between pouch neoplasia and prior colorectal neoplasia in Inflammatory Bowel Disease patients: an exploratory cohort study by Van Lierop, L, te Groen, M, Derikx, L, Ylstra, B, Hoentjen, F, Nagtegaal, I, Simmer, F

“…Abstract Background Inflammatory Bowel Disease (IBD) patients with an ileo-anal pouch anastomosis (IPAA) bear an increased risk of pouch neoplasia, with prior…”
Get full text

P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis by Savelkoul, E, Thomas, P, Derikx, L, Den Broeder, N, Römkens, T, Hoentjen, F

“…Abstract Background Anti-Tumour necrosis factor agents are essential therapeutics in moderate-to-severe Ulcerative Colitis (UC). Annual loss of response (LOR)…”
Get full text

P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update by Derks Eduarda Wilhelmina, M, van Lierop, L, te Groen, M, Kuijpers, C, Nagtegaal, I D, Hoentjen, F

“…Abstract Background The COVID-19 pandemic has profoundly impacted utilization of inflammatory bowel disease (IBD) healthcare, with a large reduction in…”
Get full text

Role of Circulating Peptide YY in the Inhibition of Gastric Acid Secretion by Dietary Fat in Humans by HOENTJEN, F, HOPMAN, W. P. M, MAAS, M. I. M, JANSEN, J. B. M. J

“…Intestinal fat inhibits gastric acid secretion and induces release of peptide YY (PYY) into the circulation. The aim of this study was to further establish the…”
Get full text

P188 Cumulative inflammatory burden as a risk factor for colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis: a multi-center case-control study by Van Lierop, L, Derks, M E W, te Groen, M, Tran, C D, Lytvyak, E, Dijkstra, G, Montano-Loza, A J, Hoentjen, F

“…Abstract Background Inflammatory bowel disease (IBD) patients with concomitant primary sclerosing cholangitis (PSC-IBD) have a 25-year cumulative risk of up to…”
Get full text